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Abstract: In this review, we discuss novel natural products discovered within the last decade that are
reported to have antifungal activity against pathogenic species. Nearly a hundred natural products
were identified that originate from bacteria, algae, fungi, sponges, and plants. Fungi were the most
prolific source of antifungal compounds discovered during the period of review. The structural
diversity of these antifungal leads encompasses all the major classes of natural products including
polyketides, shikimate metabolites, terpenoids, alkaloids, and peptides.
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1. Introduction
The global increase in antimicrobial resistance among pathogenic bacteria, viruses, fungi, and
parasites is a serious concern for human healthcare. In the case of fungi, more than one billion
individuals worldwide are affected by fungal infections and the associated mortality, over 1.5 million
deaths each year, is equivalent to that caused by tuberculosis and more than triple that of malaria [1].
Although relatively rare in healthy individuals, the incidence of superficial and invasive fungal
infections has dramatically risen in recent years. This is due to a growing ‘at-risk’ population with
impairments in their immune system, breaches in physical barriers to fungal entry, or an altered
microbiome. Skin mycoses are predominantly caused by Trichophyton, Microsporum, and Epidermophyton
genera while Candida, Cryptococcus, Aspergillus, and Pneumocystis genera, and Mucorales are the most
common invasive fungal pathogens [2]. Meanwhile, emerging pathogenic fungi that are either new
species such as the recently described Candida auris [3] or well-known species spreading in their
ecological distribution represent additional threats to human health.
The growing challenges posed by fungal diseases are further heightened as antifungal treatment
is mainly limited to the azoles and echinocandins. The azoles are the most widely used antifungals
and are synthetic compounds that reversibly inhibit cytochrome P450-dependent lanosterol or eburicol
14α-demethylase with moderate specificity for the fungal enzyme over the human counterpart [4].
Nevertheless, they suffer from off-target toxicity as well as issues with fungistatic rather than fungicidal
activity in yeasts that promote the development of resistance. The major resistance mechanisms to
azoles involve genetic mutations or increased expression of the target enzyme, or amplification or
induction of efflux pumps. The echinocandins are fungal lipopeptide natural products (Figure 1)
that are non-competitive inhibitors of 1,3-β-glucan synthase, an enzyme involved in fungal cell
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wall biosynthesis. While the natural products are not optimal in terms of pharmacokinetics, three
semisynthetic derivatives are approved for clinical use: anidulafungin prepared from echinocandin B,
caspofungin prepared from pneumocandin Bo, and micafungin prepared from FR901379 [5]. Although
the selectivity of the echinocandin target for fungi provides a good safety profile, these compounds are
large peptides, requiring intravenous administration, while mutations at hotspots in the target enzyme
lead to resistance. In addition to the azoles and echinocandins, the polyenes and pyrimidines are two
other classes approved for antifungal therapy. The natural product polyenes (Figure 2) are macrolides
isolated from various Streptomyces strains. The prototypical amphotericin B has been in clinical use for
the treatment of systemic fungal infections since the 1950s and is still an important option in critical
cases. Several additional polyenes, nystatin, natamycin, hamycin, and filipin, have received regulatory
approval. As a class, the polyenes have significant nephrotoxicity due to their relatively nonselective
mechanisms of ergosterol binding and pore formation within the cell membrane [6,7]. Finally, synthetic
pyrimidine antimetabolites such as flucytosine interfere with nucleic acid biosynthesis, but resistance
via point mutations in the fungal uracil phosphoribosyltransferase or cytosine deaminase enzymes
restricts their application to combination therapy [8].
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Overall, the current drugs have numerous limitations including toxicity, drug–drug interactions,
poor pharmacokinetics, narrow spectrum of activity, and fungistatic versus fungicidal action. These
inherent liabilities are exacerbated in immunocompromised patients since their immune system cannot
effectively assist in the eradication of the infection, thus requiring complex and prolonged treatment
regimens [9]. A further alarming trend is the rising incidence of fungal clinical isolates that are resistant
to the currently used antifungals [10,11]. The scale of the problem is highlighted by the fact that the
newest class of approved antifungals, the echinocandins, were actually discovered fifty years ago.
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The American Food and Drug Administration (FDA) has recognized the need for new antifungals by
placing Candida and Aspergillus on their list of qualifying pathogens [12]. Therapies directed against
these species will benefit from incentives including an additional five-year marketing exclusivity
besides eligibility for designation as a fast-track drug.
2. A Pipeline of Antifungal Natural Product Leads
While antifungal agents with novel mechanisms of action are in various stages of clinical
development, their number is relatively small compared to other therapeutic indications [13]. A pipeline
of additional preclinical leads is clearly needed, and natural product screening is an important
contributor in this regard. One unique feature of natural products is their high structural diversity,
sampling areas of chemical space that are difficult to access through purely synthetic compounds [14,15].
Natural products are also well validated to possess biological activity, with many examples approved
as therapeutic agents either in their native form or as semisynthetic derivatives [16]. For this review,
we searched the online database Natural Product Updates for publications that reported novel natural
products with antifungal activity from January 2010 to November 2019. From the publications,
we selected novel natural products that were active against human pathogenic fungi with an MIC <
10 µg/mL or IC50 < 10 µM. In the discussion, we include any information on additional biological
activity observed or mechanistic studies on the mode of action. The compounds are classified below
according to the type of producing organism.
2.1. Natural Product Antifungal Leads from Bacteria and Algae
Actinomycetes are the most prolific source of bacterial natural products, and this remains the
case for recently discovered antifungal leads (Figures 3–6, 1–29). In addition, there were three
examples isolated from non-actinomycete species (Figure 7, 30–35) and two from algae (Figure 8,
36–37). A strain of Streptomyces albolongus YIM 101047 isolated from elephant dung produced a
number of bafilomycins in laboratory fermentation. The new example 21-deoxybafilomycin A1 (1) and
the sesquiterpene (1β,4β,4aβ,8aα)-4,8a-dimethyloctahydronaphthalene-1,4a(2H)-diol (2) displayed
antifungal activity against Candida parapsilosis with an MIC of 3.2 µg/mL, while being inactive against
other species [17]. Genome sequencing of the strain suggested the presence of forty-six putative
biosynthetic gene clusters [18]. In the course of biosynthetic labelling experiments, it was discovered
that supplementation by acetate produced new metabolites in a Streptomyces hyaluromycini MB-PO13
strain. Among these, rubromycin CA1 (3) was active against Gram-positive bacteria andCandida albicans
NBRC 1594 with an MIC of 6.3 µg/mL, whereas an analogue with an additional alcohol was inactive [19].
A strain of Actinoalloteichus isolated from marine sediment was the source of neomaclafungins A–I
(4–12), a series of macrolides of the oligomycin family of antibiotics. The neomaclafungins were active
against Trichophyton mentagrophytes with MIC values between 1 and 3 µg/mL, compared to 10 µg/mL
for oligomycin A [20].
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Fermentation of a Streptomyces sp. isolated from mangrove rhizosphere soil led to the isolation of
a series of azalomycin F natural products (13–20) with MIC values of 1.6–6.3 µg/mL against C. albicans
as well as antibacterial and cytotoxic activity [21,22]. Astolides A (21) and B (22) are polyol macrolides
isolated from Streptomyces hygroscopicus collected from alkaline soil [23]. The compounds have MICs of
1–2 µg/mL against C. albicans, Candida tropicalis, and Aspergillus niger. Related macrolides caniferolides
A–D (23–26) were isolated from the marine-derived Streptomyces caniferus CA-271066 [24]. Like the
astolides, the caniferolides displayed potent antifungal activity with MICs of 0.5–2 µg/mL against
C. albicans and 2–8 µg/mL against Aspergillus fumigatus, as well as similar levels of cytotoxicity against
human tumor cell lines. Caniferolide A was also shown to have in vitro activity against targets relevant
to Alzheimer’s disease [25]. Enduspeptides A–C (27–29) are depsipeptides that differ in the acyl chain
attached to the threonine residue and were isolated from a Streptomyces sp. The peptides had an IC50
of 2–8 µg/mL against Candida glabrata [26].
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Within the period under review, three antifungal leads were isolated from non-actinomycete
bacterial strains. Fermentation of a myxobacterial Nannocyctis sp. led to the isolation of nannocystin
A (30) with a novel macrocyclic scaffold. While the compound inhibited C. albicans with an MIC50
of 73 nM, it also inhibited human cancer cell lines at a nanomolar level [27]. The mechanism of
action involves binding to the eukaryotic translation elongation factor 1α and structure–activity
relationships have been established through the total synthesis of analogues [28]. The burkholdines
are lipopeptide antifungal agents previously isolated from Burkholderia ambifaria 2.2N, with three new
examples Bk-1119, Bk-1213, and Bk-1215 (31–33) displaying potent activity against C. albicans and
Pharmaceuticals 2019, 12, 182 7 of 21
A. niger [29]. Among the burkholdines, Bk-1119 was the most active against A. niger with an MIC of
0.1 µg/mL and also had the best antifungal/hemolytic ratio. Additional analogues were prepared by
total synthesis [30]. The Gram-negative bacterium Chitinophaga pinensis DSM 28390 produces the novel
lantibiotics pinensins A and B (34, 35). Although lantibiotics are typically antibacterial, the pinensins
were only weakly so while having MICs of 2–4 µg/mL against yeasts and filamentous fungi [31].
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The marine alga Laurencia is a prolific producer of secondary metabolites. The sesquiterpene
eudesma-4(15),7-diene-5,11-diol (36) isolated from a Red Sea sample of Laurencia obtusa was antifungal
with MIC values of 2–7 µM against Candida and Aspergillus species [32]. The prenylated xylene
caulerprenylol B (37) was isolated from the green alga Caulerpa racemosa and had MIC80 values of
4 µg/mL against C. glabrata and Cryptococcus neoformans while being inactive against A. fumigatus [33].
2.2. Natural Product Antifungal Leads from Sponges
Marine sponges are an important source of novel natural products, and more than ten examples
with antifungal activity were described in the above-mentioned period (Figures 9 and 10, 38–55).
Extracts from the symbiotic two-sponge association Plakortis halichondroides−Xestospongia deweerdtae
yielded a number of peroxide natural products, of which plakinic acids I, J, K, and L (38–41) were potent
against Candida and Cryptococcus species with MIC ≤ 0.5 µg/mL [34]. Plakinic acid M (42) was active
against Cryptococcus gattii, Cryptococcus grubii, and Candida krusei with MIC90 values of 2.4–3.4 µg/mL
but less active against C. albicans [35]. Extraction from the South China Sea sponge Hippospongia
lachne was the source for hippolachnin A (43), a polyketide with an unprecedented scaffold [36].
The compound was potently antifungal with an MIC of 0.4 µg/mL against C. neoformans, Trichophyton
rubrum, and Microsporum gypseum. However, the natural product and analogues obtained by total
synthesis were inactive, suggesting the initial report was in error [37]. Bioassay-guided fractionation
of the same extract led to isolation of a racemic sesterterpene hippolide J (44) [38]. The natural product
was resolved into its two enantiomers, and both were highly potent antifungals with MIC50 values of
0.13–0.25 µg/mL against Candida and Trichophyton while weakly cytotoxic to the human embryonic
kidney HEK293 cell line.
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A new member of the manzamine alkaloids, zamamidine D (45), was isolated from an Okinawan
marine sponge Amphimedon sp. Zamamidine D had an IC50 of 2 µg/mL against C. neoformans but was
weakly active against other fungal and bacterial strains tested [39]. From another Okinawan marine
sponge Pseudoceratina sp., ceratinadin A and B (46, 47) were isolated with MIC values of 4 and 8 µg/mL,
respectively, against C. neoformans and 2 and 4 µg/mL, respectively, against C. albicans [40]. From an
extract of the sponge Pseudaxinella reticulata, several crambescin guanidine containing alkaloids were
isolated. Crambescin A2 392 and 406 (48, 49) inhibited C. neoformans with MIC50 values of 1.2 and
0.9 µg/mL, respectively, while being relatively inactive against C. albicans [41]. The enantiomers of two
known crambescins, crambescin A2 420 (50) and Sch 575948 (51), were also isolated with MIC50 values
of 1.1 and 2.5 µg/mL, respectively, against C. neoformans. Among metabolites isolated from the marine
sponge Agelas, two new diterpene alkaloids from Agelas citrina, agelasidine E and F (52, 53), were
Pharmaceuticals 2019, 12, 182 9 of 21
reported to have MIC values of 8 and 4 µg/mL, respectively, against C. albicans [42]. Isoagelasine C (54),
isolated from Agelas nakamurai, had an MIC value of 4.7 µg/mL against C. albicans [43]. Ageloxime B
(55), isolated from Agelas mauritiana, had an IC50 value of 5.0 µg/mL against C. neoformans as well as
antibacterial activity [44].Pharmaceuticals 2019, 12, x FOR PEER REVIEW 9 of 21 
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Plants c rl ten antifungal leads within the last decade (Figures 11 and 12,
56–64). The flavonoid (E)-6-(2-carbox ethenyl) apigenin (56) was is lated from an extract
of Mimosa c esalpiniifolia Benth., a Brazilian medicinal plant commonly known as “sabiá” or
“sansão-do-campo” [45]. The compound inhibits C. krusei with an IC50 of 44 nM, l hough t was
inactive again t C. glabrata. The isoflavono d vatacarpan (57) with n MIC of 1 µg/mL against C.
albicans was solated by bioassay-guided fracti nation fro the roots of Vatairea macrocarpa (Benth.)
Ducke [46]. The biaryl ether laevicarpin (58) was isolated from leaves f Piper laevicarpu, known as
“falsa-pimenteira” in Brazil [47]. Interestingly, the compound was previously prepa ed synthetically
prior to th s isolation. Laevicarpin had n IC50 of 7.9 µM ga nst C. g ttii, in addition to an IC50 of
50 µM against the trypomastigote form of Trypanosoma ruzi. The dimeric l kamalachalc ne E
(59) was isolated from the red dye extracted f om whole uncrushed fruits of Mallotus philippinensis [48].
The chalcone exhibited an IC50 of 4–8 µg/mL against two strains of C. neoformans.
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Investigation of the juvenile leaves of Eucalyptus maideni F. Muell led to the discovery of a number
of phloroglucinol derivatives, among which eucalmaidial A (60) showed antifungal activity against
C. glabrata with an IC50 of 0.8 µg/mL [49]. A monoterpene indole alkaloid, 16,17-epoxyisositsirikine (61),
isolated from the evergreen shrub Rhazya stricta Decne. had an IC50 of 6.3 µg/mL against C. glabrata but
was less active against other Candida species tested [50]. Erchinine B (62), a monoterpene indole alkaloid
with an unusual embedded 1,4-diazepine ring, was isolated from roots of Ervatamia chinensis and had
an MIC of 6.3 µg/mL against T. rubrum, with a lower MIC of 0.8 µg/mL against the Gram-positive
bacteria Bacillus subtilis [51]. An aporphine alkaloid (63) was isolated from the bark of a Costa Rican
sample of Beilschmiedia alloiophylla [52]. The alkaloid had an MIC of 8 µg/mL against C. albicans, as well
as antileishmanial activity and inhibition of acetylcholinesterase. The cyclic peptide tunicyclin D
(64) was isolated from roots of the medicinal herb Psammosilene tunicoides W. C. Wu et C. Y. Wu [53].
The peptide exhibited MIC80 values of 0.3–16 µg/mL against Candida species and 1.0 µg/mL against
C. neoformans.
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2.4. Natural Product Antifungal Leads from Fungi
Within the last decade, fungi were the most prolific source of novel antifungal leads (Figures 13–17,
65–98). An extract of the endophytic species Pestalotiopsis mangiferae obtained from the leaves of
the plant Mangifera indica Linn. yielded an unprecedented epoxyacetal 4-(2,4,7-trioxa-bicyclo[4
.1.0]heptan-3-yl) phenol (65) with an MIC of 0.04 µg/mL against C. albicans strains and 1.3 µg/mL
against the bacterium Micrococcus luteus [54]. Two phenalenones, auxarthrone A and D (66, 67) were
obtained from fermentation extracts of an Auxarthron pseudauxarthron strain isolated from rabbit
dung [55]. The compounds have MIC values of 3.2 and 6.4 µg/mL, respectively, against C. neoformans
and C. albicans. Further investigation into these compounds demonstrated that they are unnatural
artifacts, arising from the reaction of natural products with ketone solvents employed during the
extraction. Grifolaone A (68) was isolated from the edible mushroom Grifola frondosa. Interestingly,
the hemiketal lactone was obtained in an optically active form and assigned as the S enantiomer [56].
The furanone was a potent inhibitor, MIC of 0.15 µg/mL, of the opportunistic human pathogen
Pseudallescheria boydii and also had an MIC of 10 µg/mL against A. fumigatus.
The tropolone nemanolone B (69) was isolated from fermentation of a Nemania sp. fungus and
displayed antifungal activity with an IC50 of 4.5 µg/mL against C. albicans, and similar levels of activity
against the parasite Plasmodium falciparum and human tumor cell lines [57]. The quinone pleosporallin E
(70), isolated from a marine-derived Pleosporales sp., inhibited C. albicans with an MIC of 7.4 µg/mL [58].
Five new isocoumarins were isolated from fermentation of an endophytic Pestalotiopsis sp. obtained
from Photinia frasery. Among these, pestalactone C (71) inhibited C. glabrata with an MIC50 value of
3.5 µg/mL [59]. Aspergillusether D (72), isolated from fermentation of Aspergillus unguis PSU-RSPG204,
inhibited C. neoformans with an MIC value of 8 µg/mL, and inhibited C. albicans at a lower level [60].
A series of p-terphenyl natural products was isolated from a strain of Floricola striata inhabiting the
lichen Umbilicaria sp., among which the quinones floricolin B and C (73, 74) displayed MIC80 values of
8 µg/mL against C. albicans [61]. Further investigation of floricolin C suggested a fungicidal action
through disruption of mitochondria [62].
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Histoplasma capsulatum [63]. The same strain, in a more conventional fermentation period (25 days),
produced aintennol A (76) with an IC50 of 8 µg/mL against H. capsulatum [64]. Genome mining
for potential Diels–Alderase enzymes identified a potential candidate in the genome sequence of
Penicillium variabile. The putative biosynthetic gene cluster was engineered into an Aspergillus nidulans
expression host, enabling the isolation of varicidin A (77) with an MIC50 value of 8 µg/mL against
C. albicans [65]. The N-demethylated analogue, varicidin B, was two-fold less active. In the same
manner, the ilicicolin H biosynthetic gene cluster including a putative Diels–Alderase from a producing
strain, Neonectria sp. DH2, was heterologously expressed in A. nidulans. In addition to ilicicolin H,
a shunt metabolite ilicicolin J (78) was isolated with an MIC of 6.3 µg/mL against C. albicans [66].
Heterologous expression was also employed to confirm the biosynthetic gene cluster involved in
the production of the burnettramic acids A and B (79 and 80) in Aspergillus burnettii FRR 5400 [67].
Burnettramic acid A had an MIC value < 1 µg/mL against C. albicans while burnettramic acid B was
slightly less active with values of 1–2 µg/mL.
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Coculture of two extremophilic fungal strains of Penicillium fuscum (Sopp) Raper & Thom and
Penicillium camembertii/clavigerum Thom isolated from a single sample of surface water from Berkeley Pit
Lake led to the production of novel metabolites. Berkeleylactone A (81) displayed modest antifungal
activity with an IC50 of 6 µg/mL against C. glabrata and higher antibacterial activity [68]. Fermentation
of a Saudi strain of Petriella setifera led to the identification of the triterpene glycoside amnomopin
(82) with MIC values of 0.5–2 µg/mL against Candida species [69]. Sclerodol B (83), a triterpene from
extracts of the endophyte Scleroderma UFSM Sc1(Persoon) Fries obtained from Eucalyptus grandis, had
an MIC of 6.3 µg/mL against C. krusei with weaker activity against other species [70]. A strain f the
marine-derived fungus Stac ybotrys chartarum produced several novel diterpenoids, of which tranone
Q (84) had an MIC of 8 µg/mL against C. albicans and weaker antibacterial activity [71].
An endophyt c Penicillium sp. isolated from grass produced picolinic acid derivatives in
fermentatio . Penicolinate B and C (85, 86) had MIC values of 1.5 and 3.7 µg/mL, espectively,
against C. albicans [72]. The didymellamide series of pyrid ne alkaloids was isolated from cultures
of the m rine-derived fungi St gonosporop is cucu bitac arum and Coniochaeta cephalothecoid [73,74].
Didym llam de A, F, and G (87–89) were antifungal with MIC values of 3 µg/mL aga nst Candida
species. The fermentation also yielded (+)-N-hydroxyapiosporamide (90), the en ntiomer of the
previou ly isolated na ural product, with an MIC value of 6.3 µg/mL against C. albicans. Fermentation
of a Cyathus cf. striatus basidiomycete led to the isolation f the alkaloid pyri triatin A (91) with an MIC
of 8.3 µg/mL against Rhodotorula glutinis and similar levels f activity against Gram-positive bacteria
and human tumor cell lines [75].
Pharmaceuticals 2019, 12, 182 13 of 21
Pharmaceuticals 2019, 12, x FOR PEER REVIEW 13 of 21 
 
 
Figure 15. Structures of natural products 81–91 isolated from fungi. 
The alkalophilic extremophilic fungus Emericellopsis alkalina VKPM F-1428 was the source of the 
peptaibol emericellipsin A (92), which exhibited antifungal MIC values of 2–4 μg/mL against Candida 
and Aspergillus species as well as activity against Gram-positive bacteria. Bioassay-guided 
fractionation of extracts of Colispora cavincola isolated from plant litter led to the discovery of the 
linear peptides cavinafungin A and B (93, 94) [76]. The cavinafungins inhibited Candida species with 
an MIC of 0.5−4 μg/mL and A. fumigatus at 8 μg/mL. However, the antifungal effects were lost in the 
presence of mouse serum. Cavinafungin A also potently inhibits the Zika and dengue virus, with the 
mechanism of action attributed to inhibition of the host signal pepdidase [77]. The antifungal activity 
of Phaeosphaeria sp. F-167,953 was ascribed to the lipodepsipeptide phaeofungin (95) with some 
structural similarity to the previously known phomafungin [78]. Phaeofungin had an MIC of 4 μg/mL 
against Trichophyton mentagrophytes and lower activity against other fungi tested. 
Figure 15. Structures of natural products 81–91 isolated from fungi.
The alkalophil c extremophilic f erice lopsis alkalina VKPM F-1428 was the source of
the peptaibol emericellipsin A (92), whic exhibited a tifungal MIC values of 2–4 µg/mL against
Candida and Aspergillus species as well as activity against r - sitive t ri . Bioassa - i
fractionation of extracts of Colispora cavincola isolated from plant litter led to the discovery of the linear
peptides cavinafungi A and B (93, 94) [76]. The cavinafungins inhibited Candida species with an
MIC of 0.5−4 µg/mL and A. fumigatus at 8 µg/mL. However, the antifungal effects were lost in the
presence of mouse serum. Cavinafungin also potently inhibits the Zika and dengue virus, with
the mechanism of action attributed to inhibition of the host signal pepdidase [77]. The antifungal
activity of Phaeosphaeria sp. F-167,953 was ascribed to the lipodepsipeptide phaeofungin (95) with
some structural similarity to the previously known phomafungin [78]. Phaeofungin had an MIC of
4 µg/mL against Trichophyton mentagrophytes and lower activity against other fungi tested.
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High-throughput screening by Astellas Pharmaceuticals against a silkworm model of A. fumigatus
infection led to bioassay-guided fractionation activity of an extract of Acremonium persicinum MF-347833.
The siderophore hexapeptide ASP2397 (96) was discovered as an aluminum chelate with exceptional
potency against A. fumigatus, with an MIC of 0.2 µg/mL and efficacy at 3.2 mg/kg in a mouse in vivo
model [79]. The metal-free form AS2488059 (97) as well as the congener AS2524371 (98) were also
isolated, and the target was identified as a fungal siderophore transporter [80,81]. The compound
was out-licensed to Vical and renamed VL-2397, reaching Phase II clinical trials that were recently
discontinued. From another strain of A. persicinum, similar cyclic peptides acremonpeptides A–D were
isolated in which the asparagine residue is replaced by serine, alanine, phenylalanine, or tryptophan [82].
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Surprisingly, these compounds were inactive in antifungal or antibacterial assays at concentrations up
to 100 µg/mL, suggesting that the asparagine residue is important for antimicrobial activity.
3. Discussion
Between 2010 and 2019, our literature survey identified nearly a hundred novel natural products
reported with promising antifungal activity against human pathogens. The compounds originate
from a variety of organisms comprising bacteria, algae, fungi, sponges, and plants. The distribution
between these sources (Figure 18) indicates that fungi and bacteria were the most common source
of antifungal compounds. Indeed, this follows historical trends where the approved antifungals of
natural product origin arise from either fungi (the echinocandins) or actinomycetes (the polyenes).
The techniques employed in the publications under review range from classical phytochemical studies
with plants to high-throughput screening of extract collections and modern microbiological strategies
such as cocultivation and heterologous expression of biosynthetic gene clusters. All the major classes of
natural products including polyketides, shikimate metabolites, terpenoids, alkaloids, and peptides are
represented. As the majority of examples in this review involve the initial disclosure of activity, further
investigations are needed to assess the therapeutic potential of highly active compounds as well as
their selectivity as antifungal agents. Such studies will need to take into account the ability to produce
larger quantities of the natural product. While this is often possible by scaling up the original isolation
protocol, additional options are available that involve chemical total synthesis, engineered production
in the native strains, or using heterologous hosts. These strategies open up the possibility of the
discovery of ‘unnatural’ analogues that may be superior in their pharmacodynamic or pharmacokinetic
properties compared to the original natural product.
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It is interesting to observe the physicochemical space occupied by these natural product leads
(Table 1). Although the compounds are diverse in their structural features, they are largely compliant
with the typical guidelines for small molecule drug-like chemical space. While many of the natural
products are large in molecular weight, resulting in an average of 569, other properties such as hydrogen
bonding potential, molecular flexibility, and polarity often remain within the recommended limits.
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Table 1. Physicochemical properties of antifungal natural products. MW = molecular weight,
clogP = calculated log P, HBD = hydrogen bond donors, HBA = hydrogen bond acceptors, nrot =
number of rotated bonds, TPSA = total polar surface area in Å2. The values were taken from SciFinder
(https://scifinder-n.cas.org), based on calculations using Advanced Chemistry Development (ACD/Labs)
Software V11.02. In certain cases where the data was absent in SciFinder, values were calculated using
the Molinspiration website (https://www.molinspiration.com/). For natural products for which a series
of related compounds was reported, one representative example was selected. Shaded cells indicate
values above the recommended guidelines for small molecule drug-like chemical space (MW ≤ 500,
Clog p ≤ 5, HBD ≤ 5, HBA ≤ 10, nrot ≤ 10, TPSA ≤ 140).
Compound MW clogP HBD HBA nrot TPSA
1 607 4.8 3 8 10 115
2 198 2.1 2 2 2 41
3 508 2.9 4 12 5 186
8 751 7.0 5 10 10 155
17 1123 7.6 13 18 26 312
21 1580 0.9 15 29 33 472
28 987 4.7 6 19 11 253
30 817 4.3 4 12 9 167
31 1200 −5.7 23 32 36 546
35 2144 −0.4 26 55 30 876
36 236 2.4 2 2 3 41
37 274 3.0 2 2 4 41
42 419 7.7 1 4 14 56
44 385 6.2 1 3 9 47
45 713 8.1 7 7 10 110
46 667 0.7 6 13 10 188
48 393 3.1 6 8 13 130
53 438 5.0 4 6 12 121
54 423 2.0 2 5 5 61
55 439 2.3 2 6 5 70
56 340 1.9 4 7 6 124
57 423 6.0 2 5 7 68
58 297 2.7 1 4 1 48
59 1065 8.0 11 18 23 319
60 487 6.5 4 7 12 132
61 352 3.0 0 5 3 64
62 370 0.5 0 6 3 51
63 281 2.5 1 3 2 33
64 901 −0.1 10 21 9 303
65 194 1.3 1 4 2 51
66 358 3.0 3 7 6 121
68 200 −1.6 1 5 4 73
69 206 −1.0 2 4 2 67
70 316 3.5 2 5 5 84
71 264 0.8 3 6 5 104
72 427 7.9 3 6 8 96
74 306 4.7 1 4 4 64
75 329 6.8 1 3 3 54
76 327 6.7 2 2 9 41
77 376 3.3 2 6 5 95
78 432 5.4 3 5 4 87
79 770 3.2 8 13 35 218
81 405 2.3 3 7 6 146
82 779 6.4 8 13 14 216
83 457 9.5 1 2 6 30
84 391 2.7 1 5 3 81
85 399 5.1 1 6 14 89
87 444 1.4 3 8 6 128
90 446 3.5 4 8 7 131
91 442 3.5 2 6 6 89
92 1064 4.9 10 20 38 294
93 792 6.6 5 14 31 200
95 904 −2.0 13 23 23 368
97 891 −2.5 11 23 21 339
Average 569 3.4 5 10 11 155
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